BioMedNewsBreaks

TuesdayJun 23, 2026 9:24 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (“MS”), a disease affecting more than 2.9 million people worldwide. The article highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS, and notes that the program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease. To view the full press release, visit https://ibn.fm/KdvrI About Quantum BioPharma Ltd. Quantum is…

Continue Reading

MondayJun 22, 2026 1:09 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) was featured in a BioMedWire editorial examining the rapidly expanding DNA Damage Response inhibitor market, where new drug classes are emerging beyond PARP inhibitors. The company is advancing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to the editorial, Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology and is positioning itself as an early leader in a novel class of cancer therapeutics. Onco-Innovations highlighted preclinical data showing ONC010 more than doubled…

Continue Reading

MondayJun 22, 2026 12:07 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Announces C$5 Million Private Placement to Advance ONC010 Development 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced a non-brokered private placement of 6,764,069 units priced at C$0.7392 per unit for gross proceeds of approximately C$5 million. Each unit consists of one common share and one warrant exercisable at C$0.90 per share for three years. The financing is expected to close on or about July 10, 2026, subject to regulatory approvals, including approval from Cboe Canada. Onco-Innovations said proceeds will be used to advance its ONC010 program through manufacturing and preclinical testing activities, support development of its SynoGraph(TM) platform and provide working capital for general…

Continue Reading

MondayJun 22, 2026 11:58 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances ONC010 Program With Successful 300-Gram API Scale-Up Batch 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient supporting its proprietary ONC010 drug candidate. The batch, produced as part of Dalton Pharma Services' Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents following comprehensive quality control and Certificate of Analysis review, marking an important manufacturing milestone for the company's PNKP inhibitor program. Onco-Innovations said the scale-up campaign demonstrates the reproducibility and scalability of the manufacturing process and is expected to support future…

Continue Reading

MondayJun 22, 2026 11:46 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention 

VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC(TM)-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity. VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities…

Continue Reading

MondayJun 22, 2026 10:30 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), was featured in a BioMedWire editorial highlighting its development of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is being developed as a non-immunomodulatory neuroprotective therapy and is preparing to enter Phase 2 clinical trials following successful Phase 1 safety and tolerability studies. The editorial notes that Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in…

Continue Reading

ThursdayJun 18, 2026 1:03 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Positions AI Voice Analysis as Scalable Testing Alternative

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent TechMediaWire Podcast, where CEO Justin Hanka discussed the company’s plans to commercialize AI-powered voice analysis technology designed to detect alcohol and drug intoxication through non-invasive speech assessment. During the interview, Hanka explained that the company has built prediction models using more than 50 million data points collected through years of clinical research, enabling the identification of intoxication indicators associated with alcohol and drug use. MindBio believes its technology offers a scalable alternative to traditional testing methods that…

Continue Reading

ThursdayJun 18, 2026 12:32 pm

BioMedNewsBreaks — Why Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. A clinical-stage oncology company , Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. “The company is leading the development of Polynucleotide Kinase Phosphatase (‘PNKP’) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance,” reads a recent article. “Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.” To…

Continue Reading

ThursdayJun 18, 2026 9:42 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform 

VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components. VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for…

Continue Reading

ThursdayJun 18, 2026 9:10 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal 2026 Revenue Growth, Higher Earnings

Earth Science Tech (OTC: ETST) reported financial results for the fiscal year ended March 31, 2026, highlighted by revenue of $35.7 million, up 8% from the prior year, gross profit of $25.5 million, up 5%, and net income of $3.6 million, an 11% increase compared with fiscal 2025. Total assets rose 27% year over year to $9.0 million as the company continued expanding its integrated healthcare platform across telemedicine, pharmacy and fulfillment services. The company also emphasized its capital allocation strategy, noting it repurchased and retired more than 4 million shares during fiscal 2026 and more than 7.1 million shares through…

Continue Reading